stockrow
Friday 6 November 2026
Export BHVN’s income statement to Excel — free account
Biohaven Ltd.
BHVN Healthcare Biotechnology
- EPS
- +47.8%
- Free cash flow
- +26.6%
- Total debt
- −1.48%
Quarter to September 2026, against a year earlier
14.28
0.38
+2.73%
Follow BHVN
Alert me
Biohaven Ltd. (BHVN) Shares outstanding
Biohaven Ltd.'s shares outstanding at the end of fiscal 2025 was $107.6M, up 18.0% from $91.2M in fiscal 2024. At the end of the quarter to 30 September 2026 it was $151.0M. Over the past ten years it has ranged from $11.0M (fiscal 2015) to $107.6M (fiscal 2025) — the current reading is the highest in ten years. Biohaven Ltd. ranks 76th of 600 Biotechnology companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $107.6M | 17.97% |
| FY2024 | $91.2M | 28.14% |
| FY2023 | $71.2M | 59.14% |
| FY2022 | $44.7M | 13.63% |
| FY2021 | $39.4M | 0.00% |
| FY2020 | $39.4M | (18.80%) |
| FY2019 | $48.5M | 23.74% |
| FY2018 | $39.2M | 40.73% |
| FY2017 | $27.8M | 120.86% |
| FY2016 | $12.6M | 14.52% |
Quarterly newest first
| Period | Shares outstanding | Change |
|---|---|---|
| Sep 2026 | $151.0M | 0.27% |
| Jun 2026 | $150.6M | 2.05% |
| Mar 2026 | $147.6M | 37.16% |
| Dec 2025 | $107.6M | 1.71% |
| 39 more quarters | Free account |
Against its own ten years
Low $11.0M
High $107.6M
Ten-year median
$39.4M
Current reading's percentile
100
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| ADMA ADMA Biologics Inc compare | $225.8M |
| BHVN Biohaven Ltd. | $151.0M |
| AUPH Aurinia Pharmaceuticals Inc compare | $135.2M |
| IMNM Immunome, Inc. compare | $113.3M |
| CLDX Celldex Therapeutics, Inc. compare | $77.8M |
| VERA Vera Therapeutics, Inc. compare | $71.8M |
| LKFT Lakefront Biotherapeutics - Sponsored ADR compare | $65.9M |
| VCEL Vericel Corporation compare | $53.0M |
| PVLA Palvella Therapeutics, Inc. compare | $14.4M |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item